STRONGBRIDGE
PharmaSTRONGBRIDGE is a pharmaceutical company focused on Infectious Disease. Key products include RECORLEV.
STRONGBRIDGE's Key Drugs
STRONGBRIDGE's core commercial portfolio centers on RECORLEV, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.
STRONGBRIDGE's Recent FDA Approvals
New NDA/BLA approvals for STRONGBRIDGE over the last two years — novel drugs only, excluding generics and label supplements.
STRONGBRIDGE's Therapeutic Areas
STRONGBRIDGE's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
STRONGBRIDGE's Top Competitors
STRONGBRIDGE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
STRONGBRIDGE Pipeline Snapshot
Active clinical trials for STRONGBRIDGE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • RECORLEV leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2021-12-30
- Latest
- 2023-08-16
- Applications
- 1